Stockscreener 앱 받기
0.3349
0.77%
-0.0026
Fibrobiologics Inc 주식(FBLG)의 최신 뉴스
Risk Recap: Is FibroBiologics Inc stock a smart retirement pickJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Aug EndMonth: Why retail investors favor FibroBiologics Inc stockJuly 2025 Snapshot & Safe Swing Trade Setups - Bộ Nội Vụ
Levels Update: Why retail investors favor FibroBiologics Inc stock2025 AllTime Highs & Long-Term Safe Investment Ideas - Bộ Nội Vụ
How FibroBiologics Inc. stock benefits from strong dollarWeekly Trade Summary & Long-Term Growth Stock Strategies - Улправда
Why analysts remain bullish on FibroBiologics Inc. stockTrade Risk Summary & Consistent Profit Trading Strategies - Улправда
Will FibroBiologics Inc. stock remain a Wall Street favoriteWeekly Loss Report & Reliable Price Action Trade Plans - Улправда
Why FibroBiologics Inc. stock is a must watch in 2025July 2025 Breakouts & Verified Swing Trading Watchlists - Улправда
FibroBiologics faces Nasdaq delisting, plans reverse split - MSN
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 - Yahoo Finance
FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 - Investing.com Nigeria
Why FibroBiologics Inc. (SG0) stock attracts wealthy investorsStock Market Trends & Minimize Portfolio Damage with Warnings - ulpravda.ru
FibroBiologics CEO Issues Letter to Shareholders - markets.businessinsider.com
How a little-known biotech uses fibroblast cells against chronic disease - Stock Titan
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at D. Boral Capital - Defense World
How interest rate cuts could boost FibroBiologics Inc. stock2026 world cup usa national team round of 16 defensive leaders possession football expert forecast insights - Улправда
FibroBiologics (FBLG) Rating Maintained as "Buy" by D. Boral Cap - GuruFocus
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference - The Manila Times
FibroBiologics reports positive results for disc degeneration therapy By Investing.com - Investing.com Nigeria
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte Spheroid Therapy for Degenerative Disc Disease - marketscreener.com
FibroBiologics reports positive results for disc degeneration therapy - Investing.com
FibroBiologics Announces Positive Preclinical Results for a - GlobeNewswire
Fibrobiologics files IND for CYPS-317 to treat psoriasis - BioWorld MedTech
San Bernardino Sun - FinancialContent
FibroBiologics Advances Psoriasis Therapy Pipeline Through FDA IND Filing For CYPS317 - Voice Of HealthCare
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), FibroBiologics, Inc. (FBLG) and Corcept Therapeutics (CORT) - The Globe and Mail
FibroBiologics (NASDAQ:FBLG) Given “Buy” Rating at HC Wainwright - Defense World
FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split - TipRanks
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal By Investing.com - Investing.com South Africa
FibroBiologics receives Nasdaq delisting notice, requests hearing to appeal - Investing.com
FibroBiologics Received Notice of Delisting - TradingView — Track All Markets
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing - Investing.com Canada
FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing By Investing.com - Investing.com South Africa
FBLG: HC Wainwright & Co. Reiterates Buy Rating with Price Targe - GuruFocus
Fibrobiologics stock rises after FDA filing for psoriasis treatment - Investing.com India
Fibrobiologics stock rises after FDA filing for psoriasis treatment By Investing.com - Investing.com South Africa
FibroBiologics files IND application for psoriasis treatment By Investing.com - Investing.com Nigeria
FibroBiologics files IND application for psoriasis treatment - Investing.com India
FibroBiologics Announces IND Filing for CYPS317 Therapy for Moderate to Severe Psoriasis - Quiver Quantitative
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis - Chartmill
[DEF 14A] FibroBiologics, Inc. Definitive Proxy Statement - Stock Titan
Why FibroBiologics Inc. stock remains resilientPortfolio Value Report & Entry Point Strategy Guides - Улправда
Activity Recap: Why FibroBiologics Inc. (SG0) stock attracts wealthy investorsJuly 2025 Analyst Calls & Long-Term Capital Growth Ideas - Улправда
4.73%
0.92%
자본화:
|
볼륨(24시간):